Skip to main content
SpringerLink
Log in
Book cover

Interferon: The Dawn of Recombinant Protein Drugs pp 15–31Cite as

What Constitutes Therapeutic Success? The Interferons (1978–1998)

  • Conference paper

  • 76 Accesses

Part of the book series: Ernst Schering Research Foundation Workshop ((3368,volume 5))

Abstract

Every so often, during the past 25 years, scientific claims of therapeutic accomplishment in the treatment of cancer have entered the public domain. The biographies of these experimental therapies seem to have a familiar pattern in common: implied claims for a cancer cure based on preliminary tests, exaggerated coverage in the media, high public expectations, widespread disappointment and loss of interest when the claims failed to materialize in large scale trials, researchers and administrators forced on the defensive. and finally there seems hardly any reason for continuation of research or for clinical application.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Pieters T (1993) Interferon and its first clinical trial: looking behind the scenes. Med Hist 37: 270–295

    Article  PubMed  CAS  Google Scholar 

  2. Pieters T (1997) History of the development of the interferons: from test-tube to patient. In: Stuart-Harris R, Penny R (eds) The clinical applications of interferons. Chapman and Hall, London, pp 1–19

    Google Scholar 

  3. Krown S (1981) Prospects for the treatment of cancer with interferon. In: Burchenal J, Oettgen H (eds) Cancer; achievements, challenges, and prospects for the 1980’s. Grune and Stratton, New York, pp 367–379

    Google Scholar 

  4. Johnson R (1981) Interferon: cloudy but intriguing future. JAMA 245: 109–116

    Article  PubMed  CAS  Google Scholar 

  5. Newmark P (1981) Interferon: decline and stall. Nature 291: 105–106

    Article  PubMed  CAS  Google Scholar 

  6. Sun M (1981) Interferon: no magic bullet against cancer. Science 212: 141–142

    Article  PubMed  CAS  Google Scholar 

  7. Fenyvesi C (1981) Beyond interferon. The Washington Post (14–6–1981), p 28

    Google Scholar 

  8. Powledge T (1984) Interferon on trial. Biotechnology 2: 214–228

    Article  Google Scholar 

  9. Editorial (1982) Million dollar cold cure. The Sunday Times (3–10–1982), pp 22 – 30

    Google Scholar 

  10. Scott GM, Phillpotts RJ, Wallace J et al (1982) Prevention of rhinovirus colds by human interferon alpha-2 from Escherichia Coli. Lancet ii: 186–187

    Google Scholar 

  11. Alper J (1994) First there was interferon. The New York Times (18–111994), F 13

    Google Scholar 

  12. Wycke A (1987) Molecules and markets. The Economist (7–2–1987)

    Google Scholar 

  13. Vos R (1991) Drugs looking for diseases. Innovative drug research and the development of the beta blockers and the calcium antagonists. Kluwer Academic, Amsterdam

    Google Scholar 

  14. Oudshoorn N (1994) Beyond the natural body: archeology of sex hormones. Routledge, New York

    Book  Google Scholar 

  15. Editorial (1983) Interferon may help AIDS victims. New Scientist (3–11–1983)

    Google Scholar 

  16. Editorial (1981) Interferon tested on sclerosis. The New York Times (21–11–1981)

    Google Scholar 

  17. Finter N, Oldham RK (eds) (1985) Interferon, vol 4: in vivo and clinical studies. Elsevier, Amsterdam; (11–2–1983) update on interferon. News Service American Cancer Society, NCI Archives File no DC8301–006691

    Google Scholar 

  18. Intron A’, press information video tape produced by Schering-Plough in 1986 on the occasion of the market introduction of their interferon product

    Google Scholar 

  19. Quesada J, Hersh E, Gutterman J (1983) Hairy cell leukemia: induction of remission with alpha interferon. Blood 62: 207a

    Google Scholar 

  20. Quesada J, Reuben J, Manning J, Hersh E, Gutterman J (1984) Alpha interferon for induction of remission in hairy cell leukemia. N Engl J Med 310: 15–18

    Article  PubMed  CAS  Google Scholar 

  21. Editorial (1983) Anticancer interferon available soon. Hospital Doctor (229–1983)

    Google Scholar 

  22. Petricciani J, Esber E, Hopps H, Attallah A (1984) Manufacture and safety of interferons in clinical research. In: Came P, Carter W (eds) Interferons and their applications. Springer, Berlin Heidelberg New York, pp 357–370

    Chapter  Google Scholar 

  23. Hage H (1986) Controlerende instanties moeten soepeler worden met interferon. Toegepaste Wetenschap TNO (1–10–1986)

    Google Scholar 

  24. Baron S, Dianzani F, Stanton G, Fleischmann W (eds) (1987) The Interferon system: a current review to 1987. The University of Texas Press, Austin

    Google Scholar 

  25. Baron S, Coppenhaver DH, Dianzane F (1992) Interferon: principles and medical applications. University of Texas Press, Austin

    Google Scholar 

  26. Wallis C (1985) What’s become of interferon? Time (1–6–1985)

    Google Scholar 

  27. Balkwill F (1985) Interferons: from common colds to cancer. New Scientist 105: 26–28

    Google Scholar 

  28. Balkwill F (1989) Cytokines in cancer therapy. Oxford University Press, Oxford

    Google Scholar 

  29. Gauci L (1990) Interferon drug development: a history truely consistent with the discovery process, paper presentation at the international meeting ‘from clone to clinic’, Amsterdam

    Google Scholar 

  30. Oldham RK (1985) Interferon: a model. In: Gresser I (ed) Interferon 6. Academic, London, pp 127–141

    Google Scholar 

  31. Barnes D (1987) Biologics gain influence in expanding NCI Program. Science 237: 848–850

    Article  PubMed  CAS  Google Scholar 

  32. Foerstner A (1985) How we make our own wonder drugs. Chicago Tribune (20–1–1985)

    Google Scholar 

  33. Johnson HM, Bazer FW, Szente BE et al (1994) How interferons fight disease. Sci Am 270: 40–47

    Article  Google Scholar 

  34. Thomas HC, Cavalli F, Talpaz M (eds) (1987) Thirty years of interferon. Mediscript, London (Interferons today and tomorrow,vol 5 )

    Google Scholar 

  35. Kirchner H (ed) (1986) Update on interferons. Progress in oncology, vol 2. Mediscript, London

    Google Scholar 

  36. Kirchner H (ed) (1987) Update on interferons. Progress in virology, vol 1. Mediscript, London

    Google Scholar 

  37. Silver HK (ed) (1986) Interferons in cancer treatment. Medical Education Services, Mississauga, Canada

    Google Scholar 

  38. Came PE, Carter WA (eds) (1984) Interferons and their applications. Springer, Berlin Heidelberg New York

    Google Scholar 

  39. Pinsky C (ed) (1986) Biological response modifiers. Semin Oncol 13: 131–227

    Google Scholar 

  40. Parkinson D (ed) (1994) The expanding role of interferon-alfa in the treatment of cancer. Semin Oncol 21: 1–37

    Google Scholar 

  41. Pocock S (1983) Clinical trials. Wiley, Chichester

    Google Scholar 

  42. Van Dyck J (1995) Manufacturing babies and public consent. New York University Press, New York, p 124

    Google Scholar 

  43. Penny R (1990) Editorial. Interferons Cytokines 15: 3

    Google Scholar 

  44. Stuart-Harris R, Penny R (eds) (1997) Clinical applications of the interferons. Chapman and Hall, London

    Google Scholar 

  45. Shiell A, Salkeld G (1997) The economic aspects of interferon. In: Stuart-Harris R, Penny R (eds) The clinical applications of interferons. Chapman and Hall, London, pp 376–390

    Google Scholar 

Download references

Authors
  1. T. Pieters
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Schering AG, D-13342, Berlin, Germany

    W.-D. Schleuning

  2. Obere Geerenstrasse 34, CH-8044, Gockhausen, Switzerland

    J. Lindenmann

Rights and permissions

Reprints and permissions

Copyright information

© 1999 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Pieters, T. (1999). What Constitutes Therapeutic Success? The Interferons (1978–1998). In: Lindenmann, J., Schleuning, WD. (eds) Interferon: The Dawn of Recombinant Protein Drugs. Ernst Schering Research Foundation Workshop, vol 5. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-03787-4_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-03787-4_2

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-03789-8

  • Online ISBN: 978-3-662-03787-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation